they recently sold shares in an offering around .34 (~9,485,294 shares) and will have 9 million more shares once the dividend distributes. 18 million shares outstanding is not bad for a phase 2 drug that failed to meet its primary endpoint. Unless they have another vision for the drug itself though. I see the real value around a dollar. Giving the company around an 18-20 million dollar valuation.